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www.embomolmed.org EMBOSecretory factors that drive cancer progression are attractive immunotherapeutic
targets. We used a whole-genome data-mining approach on multiple cohorts of
breast tumours annotated for clinical outcomes to discover such factors. We
identified Serine protease inhibitor Kazal-type 1 (SPINK1) to be associated with
poor survival in estrogen receptor-positive (ERþ) cases. Immunohistochemistry
showed that SPINK1 was absent in normal breast, present in early and advanced
tumours, and its expression correlated with poor survival in ERþ tumours. In ER
cases, the prognostic effect did not reach statistical significance. Forced expres-
sion and/or exposure to recombinant SPINK1 induced invasiveness without
affecting cell proliferation. However, down-regulation of SPINK1 resulted in cell
death. Further, SPINK1 overexpressing cells were resistant to drug-induced
apoptosis due to reduced caspase-3 levels and high expression of Bcl2 and
phospho-Bcl2 proteins. Intriguingly, these anti-apoptotic effects of SPINK1 were
abrogated by mutations of its protease inhibition domain. Thus, SPINK1 affects
multiple aggressive properties in breast cancer: survival, invasiveness and che-
moresistance. Because SPINK1 effects are abrogated by neutralizing antibodies,
we suggest that SPINK1 is a viable potential therapeutic target in breast cancer.titute of Singapore,
niversity School of
Medical Sciences,





Mol Med 3, 451–464INTRODUCTION
In breast cancer treatment, resistance to prevailing drug
treatments prompts a need to find novel molecular targets for
antibody-based or small molecule-based therapeutics. Towards
this end, we mined the expression profiles of 760 primary breast
cancers from multiple patient cohorts to select genes encoding
extracellular proteins, secreted growth factors and cell surface
receptors that are consistently associated with poor patient
survival for potential therapeutic targets. The most promising
candidate was the serine protease inhibitor Kazal-type 1
(SPINK1).
SPINK1 is a 6 kDa secreted factor and its primary function
is trypsin inhibition in the pancreas and small intestines
(Paju & Stenman, 2006). Multiple variants of SPINK1 have been 2011 EMBO Molecular Medicine 451
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452previously shown to be a strong causal factor for chronic
pancreatitis possibly due to inhibition of its trypsin inactivation
function (Bagul et al, 2009; Derikx and Szmola, 2009). In
addition, inactivation of SPINK1 in the pancreas results in
autophagy of exocrine pancreatic cells, suggesting that SPINK1
may be important in cell survival. Interestingly, mice deficient in
SPINK3, the mouse homolog of human SPINK1, die due to
excessive autophagy of the pancreatic acinar cells and,
similarly, autophagy has recently been demonstrated by
silencing the SPINK1 homolog in Hydra. Autophagy is mediated
by ATG5/12 and can be regulated by Bcl2 expression
(Djavaheri-Mergny et al, 2010). In liver cells, Hepatitis B and
C viruses induced expression of SPINK1, thus protecting liver
cells from serine protease dependent cellular apoptosis (SPDCA;
Lamontagne et al, 2010). Taken together, SPINK1 appears to
play an important role in both cell survival and prevention of
apoptosis by several different pathways in normal tissues.
In cancer, SPINK1 was first discovered in the urine of ovarian
cancer patients, but has since been found to be strongly
associated with poor prognosis in multiple cancers including
that of the prostate, ovary, bladder, pancreas and colon (Gaber
et al, 2009; Gouyer et al, 2008; Kelloniemi et al, 2003; Tomlins
et al, 2008). In some cell lines derived from these tissue types,
SPINK1 enhanced proliferation and cell invasion. It has been
suggested that SPINK1 induces cellular invasion through
pathways such as phosphoinositide 3-kinase (PI3K), Rho-like
GTPases and protein kinase C (PKC). This process appears to
require its trypsin inhibitory property as a single mutation at the
trypsin binding site fails to induce cellular invasion of colon
cancer cells (Gouyer et al, 2008). These data suggest that
SPINK1 confers some oncogenic properties to cancer cells.
Since SPINK1 expression associated with poor survival
outcome in breast cancer, we comprehensively altered SPINK1
levels using siRNA-mediated knockdown, stable overexpression
and exogenous application of SPINK1 to characterize its
molecular functions. We show that SPINK1 not only affects
invasion, motility and cellular survival as reported previously,
but, in addition, confers chemoresistance to multiple drugs by
decreasing caspase-3 levels and increasing basal levels of anti-
apoptotic factors, Bcl2 and phosphor-Bcl2. Moreover, the
protease inhibitor activity of SPINK1 is essential for such
chemoresistance but unlike in prostate and colon cancer, it is
dispensable for cell invasion. Further, we show that both
SPINK1 RNA and protein levels are predictive of patient survival
specifically in ERþ cases. Our data identifies novel and breast
cancer specific mechanisms that may affect cancer progression
and suggest that SPINK1 is an important therapeutic target.Figure 1. Meta-analysis displaying the association of SPINK1 expression
with poor DMFS across multiple cohorts (p<1E05). Ten publically
available datasets were analysed and are listed on the Y-axis of the graph. The
dotted line represents hazard ratio of 1.RESULTS
SPINK1 transcript levels are positively correlated with breast
cancer metastasis
To discover novel targetable oncogenes in breast cancer, we
developed a whole-genome data-mining approach that
leverages large independent microarray studies for the sys-
tematic discovery of genes correlated with distant metastasis- 2011 EMBO Molecular Medicinefree survival (DMFS) of patients. In an initial screen involving
760 tumours derived from four independent breast cancer
cohorts (Loi et al, 2007; Miller et al, 2005; van de Vijver et al,
2002; Wang et al, 2005), we performed Cox proportional
hazards regression on each of 44,928 gene probe sets
(Affymetrix U133A and U113B Genechips) to identify candidate
oncogenes by their statistically significant and reproducible
associations with metastatic recurrence. The genes were then
cross-referenced with the Gene Ontology database (www.
geneontology.org) to identify all metastasis-associated genes
encoding known and predicted transmembrane receptors and
secreted growth factors (Table S1 of Supporting information). Of
the small number of candidate genes we identified, SPINK1 was
positively correlated with metastatic recurrence in all four
cohorts. We next extended our meta-analysis to all publicly
available breast cancer expression array datasets (annotated for
survival outcomes; Chin et al, 2006; Loi et al, 2007; Miller et al,
2005; Minn et al, 2005; Schmidt et al, 2008; van de Vijver et al,
2002; Wang et al, 2005; Zhang et al, 2009) as of 2009, and found
that the expression of SPINK1 was reproducibly correlated with
metastatic recurrence in 8 of 10 breast cancer studies (overall
hazard ratio¼ 1.19; confidence interval [1.10, 1.28]; p< 1E05;
Fig 1). Therefore, SPINK1 and its clinical and biological effects
were analysed further.
SPINK1 associates with poor prognosis mainly in ERR LN
breast cancer
To study the association of SPINK1 with prognosis in specific
subtypes of breast cancer classified by Perou et al (Perou et al,
2000), we extended the analyses to a ‘mega cohort’ of 2034
publicly available breast cancer expression profiles from 14
independent cohorts (Table S2 of Supporting information; Chin
& Gray, 2008; Desmedt et al, 2007; Ivshina et al, 2006; Loi et al,
2007, 2008; Miller et al, 2005; Minn et al, 2005, 2007; Pawitan
et al, 2005; Schmidt et al, 2008;Wang et al, 2005; Yau et al, 2007;
Zhang et al, 2009). We found that SPINK1 expression was
linearly associated with poor DMFS in ERþ patients (p< 0.001),
but did not significantly correlate with the survival of theEMBO Mol Med 3, 451–464 www.embomolmed.org
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Figure 2. Kaplan–Meier curves demonstrating the association of SPINK1 expression with patient prognosis in ERR and ER cohorts. Samples are divided
into two groups, above mean SPINK1 expression (red) and below mean SPINK1 expression (green). Prognosis is measured by disease and metastasis free survival
(years).
A. SPINK1 expression in all samples.
B. ER-negative cases.
C. ER-positive cases.ER-negative (ER) group (Fig 2). However, stratification of ER
patients into deciles based on the intensity of SPINK1 expression
showed that very high SPINK1 levels marginally displayed a
minor trend towards poor prognosis in ER patients (Fig S1 of
Supporting information). This suggests that SPINK1 exerts its
greatest differential impact on ERþ cancers, with only marginal
effect on ER breast cancers. Interestingly, the impact of
SPINK1 on prognosis was highest in the less aggressive clinical
subsets of breast cancer (ERþ/LN, Table 1), Further, we
studied if SPINK1 was a predictor of outcome or distinguished
any intrinsic subtypes within the ERþ tumours. We analysed
SPINK1 expression–survival associations in LumA, LumB,
Normal-like, HER2-enriched, No Subtype and Basal-like groups,
within ERþ breast cancer only (Table 2). By Cox analysis, in the
Normal-like ERþ tumours, SPINK1 expression was significantly
correlated with DMFS (p¼ 0.02), while positive trends forTable 1. SPINK1 and clinical outcome in breast cancer subgroups











ERþ, LN, Endocrine Monotherapy 357
ERþ, LNþ, Endocrine Monotherapy 197
www.embomolmed.org EMBO Mol Med 3, 451–464association were observed in both LumA and ‘No Subtype’ ERþ
cases (p¼ 0.10 and 0.13, respectively). In the LumB ERþ
subgroup, the Cox p-value was 0.62 which essentially argued no
survival association. Together, these observations suggest that
SPINK1 along with ER status was an important predictor of
outcome irrespective of further sub-classification into intrinsic
subtypes. SPINK1 did not show differential expression between
ERþ and ER samples, nor was its expression biased in any
intrinsic molecular subtypes of breast cancer (Fig S2 of
Supporting information). This is consistent with the notion
that the SPINK1 association with survival is not a function of
differential expression in the different tumour subtypes.
SPINK1 expression differs in normal and breast tumour tissue
To investigate the localization of the SPINK1 protein in both
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Table 2. SPINK1 and intrinsic subtypes of breast cancer
Subtype #ERþ Cox pval Cox HR Cox 95% CI
LumA 471 0.1 1.19 0.97–1.45
LumB 328 0.62 1.03 0.91–1.17
Normal-like 228 0.02 1.34 1.06–1.69
No Subtype 69 0.13 1.36 0.91–2.04
HER2like 106 0.72 0.96 0.76–1.21
Basal 141 0.67 0.94 0.71–1.24
454clinically annotated cores on a tissue microarray (TMA) using
an anti-SPINK1 antibody. Normal pancreas served as a positive
control and specificity of the staining was evaluated by pre-
neutralizing the antibody with recombinant SPINK1 protein
(Fig S3 of Supporting information). The expression of SPINK1
was negligible in normal breast tissue, but most tumours were
immunoreactive (95%; Fig 3, panels A–C). This suggested that
SPINK1 was probably expressed early in tumour development
and continued to be present in advanced disease. Of the 98 cores
stained, 81 breast cancer samples were annotated for patient
survival data. Analysis (see Materials and Methods Section)
showed that high SPINK1 protein levels correlated with overall
lower disease-free survival. Upon sub-division of patients into
ERþ and ER cohorts, this correlation was most significant in
the subset of ERþ breast cancer cases (Fig 4), supporting our
initial findings that the SPINK1 transcript displayed positive
association with poor prognosis predominantly with ERþ cases.
Moreover, SPINK1 expression did not associate with grade, age,Figure 3. SPINK1 expression in normal breast and breast tumours.
A. SPINK1 expression was negligible in 10 normal breast cores (panels a–h).
B. This panel shows representative cores from the commercial breast TMA. As sh
SPINK1 (panels a–h).
C. SPINK1 nuclear staining was largely restricted to the breast tumour cells (gre
D. Localization of SPINK1 in vitro. MDA-MB-231 cells were treated with SPINK1-
staining observed in cells after 12–24 h of SPINK1 treatment, recapitulating st
Red: anti-His antibody).
 2011 EMBO Molecular Medicineethnicity, stage and cERBB2 (Table S3 of Supporting informa-
tion). Interestingly, SPINK1 subcellular localization seemed to
vary across tumour tissues, with some expressing SPINK1 in the
cytoplasm and others in the nuclei. To confirm that this nuclear
localization is not an artefact of the immunohistochemical
staining of paraffin processed tissue, we performed immuno-
fluorescence on MDA-MB-231 cells treated with soluble
recombinant SPINK1 bearing a 6Xhis tag. Using an antibody
against the tag as well as an antibody against SPINK1, we
confirmed that exogenously applied SPINK1 localized in the
nucleus within 24 h of application (Fig 3D).
Loss of SPINK1 results in reduced cell survival
Although we observed significant correlation of SPINK1 to
DMFS mainly in ERþ patients, we investigated the mechanistic
effects of SPINK1 in both ERþ and ER cells. We attenuated
SPINK1 transcript levels by siRNA in the breast cancer cell lines
MCF-7 and MDA-MB-231 and conducted assays to detect
phenotypic changes in cell proliferation, motility, invasiveness
and anchorage-independent growth. Each of the 3 SPINK1-
targeted siRNA constructs reduced SPINK1 levels in MCF-7 and
MDA-MB-231 cells by >50%, with C2 siRNA being the most
efficient (>95%; Fig 5A). Consistent with a threshold effect, C2
siRNA led to the most significant reduction of proliferation for
both MCF-7 and MDA-MB-231 (Fig 5B), whereas, C1 and C3
siRNAs displayed marginal phenotypes. We posited that the
observed decrease in proliferation could reflect either cell cycle
arrest or apoptosis. Therefore, we studied the activation ofown, invasive ductal carcinomas were positive but displayed various levels of
en arrow) as compared to adjacent normal cells (red arrow).
CM and uptake of SPINK1 (if any) was studied using two antibodies. SPINK1
aining observed in primary tumours (Blue: DAPI; Green: anti-SPINK1 antibody;
EMBO Mol Med 3, 451–464 www.embomolmed.org
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igure 5. Phenotypic assays upon siRNA-knockdown of SPINK1.
. siRNA-mediated knockdown (kd) of SPINK1 using three different siRNAs in breast cancer cell lines MCF-7 and MDA-MB-231. SPINK1 expression was detected
via RT-PCR.
. Effect of SPINK1-kd on cell proliferation in MDA-MB-231 (left panel) and MCF-7 (right panel).
. Activated PARP and caspase-3 upon siRNA-mediated knockdown of SPINK1 in MDA-MB-231 (left panel) and MCF-7 (right panel). (p<0.005; p< 0.05;
Figure 4. Kaplan–Meier curves demonstrating the association of SPINK1 protein levels with patient prognosis in ERR and ER cohorts. Prognosis is
measured with DMFS (years).
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Figure 6. Proliferation rescue assay of SPINK1 in MDA-MB-231.
Incorporation of BrDU in MDA-MB-231 cells upon SPINK1-kd, and rescue with
bioactive SPINK1-CM. Significance of knockdown was measured against
scrambled control, while significance of SPINK1CM was measured against
VecCM as a control (p<0.005).
456apoptotic markers PARP and caspase-3 using a cell-based
immunofluorescence assay. Attenuation of SPINK1 induced
activation of both PARP and caspase-3 in MDA-MB-231
(p< 0.05, Fig 5C, left panel) and MCF-7 cells (Fig 5C, right
panel). Secondly, since loss of SPINK1 leads to excessive
autophagy in animal model systems, we studied if siRNA
mediated knockdown of ATG5/12 was able to rescue cell death
caused by loss of SPINK1. As shown in Fig S4 of Supporting
information, interfering with autophagy could not rescue cell
death. Taken together, the apparent decrease in cell proliferation
upon loss of SPINK1 was due to the induction of cellular
apoptosis. Therefore, SPINK1 appears to be essential for survival
of breast cancer cells lines regardless of estrogen receptor status.
Rescue of siRNA-mediated phenotype(s) by exogenous
SPINK1
To determine the specificity of our SPINK1 siRNA constructs by
a phenotypic rescue, we generated two sources of recombinant
SPINK1 by over-expressing SPINK1 in MCF-7 and SF9 insect
cells (Fig S5, panels A–C of Supporting information). Condi-
tioned media (CM) was collected from both sources (referred to
as SPINK1 CM and SF9spink1 CM), as well as from cells
transfected with empty vector as controls (vector-CM and
SF9vecCM, respectively). Treatment of C2siRNA cells with
SPINK1-CM resulted in 5-bromodeoxyuridine (BrDU) incor-
poration showing that these cells survived and could subse-
quently divide (Fig 6). The control Vec-CMwas unable to rescue
this cell death. This confirms the specificity of the siRNA used as
well as the functionality of the recombinant SPINK1. Interest-
ingly, neither MCF-7 cells over-expressing SPINK1 (MCF-7
SPINK1OE) nor various breast cancer cell lines treated with
SPINK1-CM showed increased proliferation (Fig S6 of Support-
ing information). This further supports the notion that SPINK1 is
probably an important survival factor rather than a potent
growth inducer in breast cancer.
SPINK1 augments drug resistance
Given the evidence that SPINK1 is a survival factor in breast
cancer cell lines, we asked whether SPINK1 could increase
cellular resistance to anti-cancer drugs in either an autocrine or a
paracrine fashion. First, we treated MCF-7 SPINK1 overexpres-
sing cells (SPINK1OE) with increasing concentrations of five
commonly used chemotherapeutic drugs, 5-fluorouracil (5-FU),
suberoylanilide hydroxamic acid (SAHA), tamoxifen (TAM),
adriamycin (ADR) and etoposide (VP16). SPINK1OE cells were
significantly more resistant to chemically induced apoptosis as
compared to control cells, as shown by decreased PARP (left
panel) and caspase-3 (right panel) activation levels (Fig 7).
Next, we pretreated MCF-7 parental cells with exogenous
SPINK1-CM before inducing apoptosis with 5-FU. Strikingly,
5-FU-mediated cell death was abrogated by pretreatment with
SPINK1-CM but not by control media (vector-CM), however
to a degree lesser than that observed in MCF-7 SPINK1OE cells
(Fig S7 of Supporting information). Therefore, increased levels
of SPINK1, both by autocrine and paracrine mechanisms, were
capable of conferring increased drug resistance in breast cancer
cells. 2011 EMBO Molecular MedicineSPINK1 induces resistance to apoptosis through regulation of
main apoptotic players
Since SPINK1 protected cells from drug-induced apoptosis, we
studied the expression of a panel of pro- and anti-apoptotic
genes including caspase-3, caspase-8, PARP, BID, Bcl2 and
phospho-Bcl2 in MCF-7 cells treated with SPINK1-CM for 2 h. As
shown, apoptosis-inhibitor Bcl2 levels were upregulated without
changing caspase-3, BID, PARP and caspase-8 levels (Fig 8A and
S8 of Supporting information). Interestingly, in different clones of
MCF-7 SPINK1 OE cells, endogenous Bcl2 and phosphor-Bcl2
increased and caspase-3 levels decreased with increasing
expression of SPINK1 (Fig 8B). The decrease in caspase-3 was,
however, not evident in cells treated with SPINK1-CM (Fig 8A),
perhaps indicating that prolonged high expression of SPINK1
may lead to higher chemoresistance. Since previous studies
showed that the protease inhibitor function of SPINK1 is
necessary for some oncogenic properties of SPINK1 (Lamontagne
et al, 2010), we generated a SPINK1 K18Y mutant lacking this
function (Gouyer et al, 2008; Fig S5D of Supporting information).
As shown in Fig 9, pretreatment of cells with SPINK1-K18Y-CM
(hatched bars)was unable to protect cells from 5 FU- (panel A) or
SAHA- (panel B) induced apoptosis. Together, these data show
that high SPINK1 induces chemoresistance and its protease
inhibitor function is critical to mediate this effect.
SPINK1 leads to increased invasion of breast cancer cells
As part of our cellular screen for SPINK1 induced phenotypes,
we had found that knockdown of SPINK1 attenuated invasion ofEMBO Mol Med 3, 451–464 www.embomolmed.org
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Figure 7. Induction of resistance to chemically induced apoptosis.
Activation of PARP (left panel) and caspase-3 (right panel) was measured in
MCF-7 vector control (white bars) and SPINK1 overexpressing MCF-7 cells
(black bars) following 24 h of exposure to varying concentrations of drugs.
Effects of SPINK1 were measured using the student’s t-test with vector as
control (p<0.005; p<0.05; p< 1E05).
A. 5-FU (5-fluorouracil)




www.embomolmed.org EMBO Mol Med 3, 451–464breast cancer cell lines and that this effect could be rescued
using SPINK-CM but not by Vec-CM (Figs S9 and 10A of
Supporting information). We extended this analysis using
recombinant SPINK1 and found that in two invasive breast
cancer cell lines, MDA-MB-231 and BT549, SPINK1-CM sig-
nificantly increased invasion by 2–3 fold (Fig 10B). Non-invasive
MCF10A and MCF-7 cells do not invade in 24h. After 48h, these
cells show a relative increase in invasion, however, the total
number of cells was extremely low (Fig S10 of Supporting
information). Importantly, we found that induction of cellular
invasion in MDA MB 231 and BT-549 cells could be specifically
immuno-neutralized by anti-SPINK1 antibodies (Fig 10C, Fig S11
of Supporting information). We then tested whether the invasive
property of SPINK1 was due to its activity as a trypsin/serine
protease inhibitor. We exposed K18YCM to MDA-MB-231 cells,
and found that K18YCM retained the ability to induce cellular
invasion like wild-type (WT) SPINK1-CM, suggesting that active
protease inhibitor function is not necessary (Fig 10D). Similar
effects were observed in BT549 cells (data not shown). Thus, the
anti-apoptotic and the pro-invasive activity of SPINK1 are
separable by its protease inhibitor function.
SPINK1 induces metastasis in vivo
To test if the in vitro invasiveness of MDA-MB-231 cells was
similarly affected in vivo, we injected MDA-MB-231 cells over-
expressing SPINK1 (MB231 SPINK1OE) into the tail-vein of
Balb/c nu/nu mice. Figure 11 shows that SPINK1 expression led
to increase in both the number and size of metastatic lesions in
the mouse lung. Mice injected with MB231-vector cells had only
4.1% 2.7 lesions larger than 200mm, while MB231 SPINK1OE
cells gave rise to significantly larger lesions with 24.8% 8.5
larger than 200mm (p< 0.05). The MB231 SPINK1OE cells also
formed almost threefold more lesions than that of the control
cells (p< 0.05). In concordance with our in vitro data, MCF-7
SPINKOE cells did not show lung metastases in vivo (data not
shown). These data suggest that in breast tumour cells with
prior capacity to invade, high SPINK1 expression may lead to
increased metastasis as compared to the same cells expressing
relatively lower amounts. However, due to unavailability of a
suitable invasive model system, SPINK1 effects in ERþ cells
remain unexplored.DISCUSSION
In this study, using genome-wide profiling of breast tumours
from multiple cohorts as well as validation by cell-based
phenotypic assays, we identified for the first time that SPINK1 is
a biological driver of aggressiveness in breast cancer. All breast
cancer cohorts analysed display a positive association of SPINK1
expression with poor outcome. Further analysis of SPINK1 in
2034 breast tumours from 14 independent cohorts revealed that
SPINK1 is significantly associated with poor prognosis only in
ERþ tumours but not in ER. In intrinsic subtype-based
analysis, SPINK1 was prognostic in Normal-like and LumA
groups. Though LumB is clinically the most relevant subtype for
poor prognosis, we found no SPINK1-survival association in this 2011 EMBO Molecular Medicine 457
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Figure 8. Protein levels of apoptotic genes in the
presence of SPINK1.
A. Protein levels of main apoptotic regulators were
measured via Western blot 2 h after SPINK1CM
(SH9), vecCM or no CMwas added to MCF-7 cells.
B. Expression of main apoptotic regulators was
measured inMCF-7 cells that overexpress SPINK1
at varying levels (SH5 and SH9), along with empty
vector overexpression as a control.
458group. Careful analysis of our cohorts showed that ER status was
not synonymous with LumA/LumB classification, the ERþ
group contained variable numbers of all five intrinsic subtypes
as well as a ‘no subtype’ group (i.e. <10% correlation with any
subtype). Secondly, ER tumours and those whose clinical ER
status was unknown, occasionally mapped to LumA and LumB.
We suggest that these factors potentially confound the impact of
SPINK1 in these subtypes as it relates to clinical ER positivity.
However, SPINK1-survival association was strongest in less
aggressive ERþ LN tumours.Figure 9. Induction of resistance to chemically induced apoptosis. Parental MC




 2011 EMBO Molecular MedicineThis prognostic association is recapitulated at the protein
level: in a panel of clinically annotated breast tumours, high
SPINK1 expressionwas consistently and significantly associated
with poor prognosis of ERþ rather than ER tumours. More
detailed analysis of meta-analytical data, however, showed a
small effect by SPINK1 on prognosis of ER patients: ER
individuals in the highest SPINK1 expressing deciles have a
slightly poorer survival than the lowest expressing deciles.
However, the numbers of ER patients in the meta-analysis
were one third those of ERþ patients, thus limiting the power toF-7 cells were pretreated with vecCM (white bars), WT SPINK1CM (black bars)
via activated PARP (left panels) and activated caspase-3 (right panels) levels.
EMBO Mol Med 3, 451–464 www.embomolmed.org
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Figure 10. SPINK1 induces cellular invasion in vitro and in vivo.
A. Cell invasion assay with MDA-MB-231 cells. Loss of invasion upon SPINK1 siRNA treatment, and rescued with SPINK1-CM.
B. Effect of SPINK1-CM on invasion in two breast cell lines. The total number of cells that invadedwasmeasured after 24 h (MB231) or 48 h (BT549) in response to
SPINK1-CM and vector control CM.
C. Effect of SF9spink1CM and immunoneutralization on MDA-MB-231 cells. (White bars—SF9vecCM; black bars—SF9spink1CM diluted 10; checkered bars—
CM with addition of neutralizing antibody against SPINK1).
D. Invasion of MDA-MB-231 treated withWT SPINK1 andmutant SPINK1. Number of cells invaded weremeasured 24 h after assay setup. (p< 0.005; p<0.05).discern SPINK1 effects in the ER group. That SPINK1 may be
operative in both ERþ and ER conditions is confirmed by the
enforced overexpression of SPINK1 or the addition of exogenous
recombinant SPINK1 protein, which induced the same cellular
effects in ERþ and ER breast cancer cell lines. Such dramatic
and non-physiologic overexpression of SPINK1 in cell culture
systems serves to exaggerate phenotypic outcomes. We suggest
that any association of SPINK1 with DMFS in ER tumourswww.embomolmed.org EMBO Mol Med 3, 451–464could be masked by more dominant oncogenic pathways
operative in ER tumours.
With the exception of gastric malignancies, high levels of
SPINK1 expression have been associated with poor prognosis
in multiple cancer types such as prostate cancer, liver cancer,
ovarian cancer and bladder cancer (Gaber et al, 2009; Gkialas
et al, 2008; Gouyer et al, 2008; J-P Wiksten, 2005; Kelloniemi
et al, 2003; Shariat et al, 2005; Tomlins et al, 2008). SPINK1 2011 EMBO Molecular Medicine 459
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Figure 11. SPINK1 enhances metastases in vivo. MDA-MB-231 vector-
control cells or SPINK1-overexpressing cells were injected intravenously into
three mice each, and total lung metastases were counted 12 weeks later.
(p<0.005).
460expression is high in ETS-rearrangement negative prostate
cancer and loss of SPINK1 attenuates invasiveness and tumour
growth (Ateeq et al, in press; Tomlins et al, 2008).
Recombinant SPINK1 has been described to have opposing
effects that are cell type specific, augmenting cell proliferation
in gastric and pancreatic (Marchbank et al, 2009; Ozaki et al,
2009) but not in prostate cancer cell lines (Tomlins et al, 2008).
Functionally, SPINK1 serves as a motility factor in various
colon, prostate and gastric cancer cell lines and this effect can
be attenuated in colon cancer cell lines by PI3K, PKC and Rho
GTPase inhibitors (Gouyer et al, 2008; Marchbank et al, 2009;
Tomlins et al, 2008).
To determine cellular functions of SPINK1 in breast cancer,
we analysed the phenotypic effects of SPINK1 attenuation,
recombinant SPINK1 treatment and SPINK1 over expression.
Our results strongly suggest that SPINK1 does not induce
proliferation in breast cancer cells, but rather is required for
survival of cancer cells. Further, SPINK1 led to increased
invasion of cancer cells without affecting cell proliferation both
in vitro and in in vivo tail vein metastasis assays. However,
unlike prostate and colon cancer, we found that the protease
inhibitor function of SPINK1 was not important for invasion in
breast cancer; however, inhibitors of PI3K, PKC and Rho
GTPase pathways attenuated this response (data not shown).
This suggests that SPINK1 may initiate a slightly distinct
molecular pathway in breast cancer cells. Such decoupling of
growth from the conjoint phenotype of invasion and survival
has been well documented in another cancer-associated
ligand–receptor system such as the GAS6 ligand with its
cognate receptor, the tyrosine kinase AXL (McCloskey et al,
1997). 2011 EMBO Molecular MedicineSince SPINK1 was important for cell survival, and SPINK1
expression was associated with poor patient prognosis, we
studied if SPINK1 could induce chemoresistance in cancer cells.
We show that recombinant SPINK1 not only enhances cell
survival, but also induces resistance to apoptosis induced by
common cytotoxic agents: SAHA, 5-FU, TAM, ADR and VP16.
Mechanistically, we demonstrate that the presence of SPINK1
greatly reduces caspase-3 expression and consequent activation
upon drug treatment. In addition, SPINK1 also leads to high
basal expression of anti-apoptotic Bcl2 and phospho-Bcl2. This
is compelling as Bcl2 is a strong prognostic factor in node-
negative, ERþ breast cancers that respond poorly to chemother-
apy (Paik et al, 2006). Thus a molecular relationship between
SPINK1, Bcl2 and chemoresistance may explain the association
of SPINK1 with poor outcome in ERþ LN patients. Whether
SPINK1 expression can be utilized to predict response/benefit
from chemotherapy in ERþ node negative patients needs further
study.
The K18Ymutant fails to protect cells or induce anti-apoptotic
signalling in cells. Taken together, these data suggest that
SPINK1 with intact protease inhibitor activity alters ‘set point’ of
the apoptotic machinery towards one favouring survival.
Conceivably, attenuation of SPINK1 expression in breast cancer
may promote the efficacy of anticancer therapies (Ghobrial et al,
2005; Kasibhatla & Tseng, 2003; Sun et al, 2004). Further
experiments are required to identify the downstream effector
that links SPINK1 to invasion and survival and explains this
differential requirement for protease modification.
Lu et al (Lu et al, 2008) suggested that SPINK1 inhibits only
serine protease-dependent apoptosis (SPDCA) owing to its
protease inhibitor function but has no role to play in caspase-
dependent apoptosis (CDCA) in human hepatoma cells. In
breast cancer, we demonstrate that SPINK1 is capable of
interfering with caspase-3 induced apoptosis suggesting addi-
tional mechanisms of chemoresistance.
Our work also found some intriguing new observations
about SPINK1 biology. Despite SPINK1 being a secreted
extracellular protein, we unexpectedly observed nuclear
localization of SPINK1, not only in a time-dependent manner
in cell lines in vitro, but also in the nuclei of primary tumours by
immunohistochemistry. Soluble secreted growth factors such as
the epidermal growth factor and fibroblast growth factor, are
transported into the nucleus and are known to mediate
transcription (Planque, 2006). However, the implications of
such nuclear localization, in breast cancer progression remain
unclear, and will need further study.
These data suggest that though SPINK1 may not be a ‘driver’
oncogene in breast cancer, its high expression critically
influences key processes in cancer progression including cell
survival, drug response and cell invasion ultimately leading to
poor clinical outcome. Its associationwith ERþ tumoursmakes
SPINK1 a plausible combinatorial therapeutic target in early
breast cancer. That most of these aggressive phenotypes—
chemoresistance, invasion and anti-apoptosis—can be
reversed with attenuation of SPINK1 levels suggest that
SPINK1 may be a reasonable therapeutic target for neutralizing
antibodies.EMBO Mol Med 3, 451–464 www.embomolmed.org
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Breast cancer cohorts
SPINK1 expression characteristics were analysed in breast cancer
using an integrated ‘super cohort’ of 2116 breast tumours profiled
using Affymetrix GeneChip technology. The super cohort is comprised
of 15 distinct breast cancer cohorts for which corresponding
microarray data and clinical annotation were publicly accessible from
microarray databases including the Gene Expression Omnibus
(National Center for Biotechnology Information, USA), ArrayExpress
(European Bioinformatics Institute, UK) and caArray (National Cancer
Institute, NIH, USA). General cohort details and literature references
are presented in Table S1 of Supporting information. Original discovery
and metaanalysis were perfomed on a subset of this ‘super cohort’.
Microarray data processing and case selection
In all cases, raw data (CEL files) were pre-processed and normalized
using the R software package (R development Core Team, 2010) and
library files provided via the Bioconductor project (Gentleman et al,
2004). In order to preserve a consistent normalization strategy across
all cohorts, raw data were MAS5.0 normalized on a per-cohort basis
using the justMAS function in the simpleaffy library from Bioconductor
(no background correction, target intensity of 600). The specific array
platforms employed here were the HG-U133A, HG-U133plus2 and
HG-U113A2 gene chips. To ensure equal information content from
each chip type, only probe sets common to all chip types were utilized
in subsequent analysis. This resulted in the use of 22,268 probe sets
that were common to all microarrays in all cohorts. Cross-cohort
batch effects were corrected using the COMBAT empirical Bayes
method (Johnson et al, 2007). Of the initial 2116 tumour profiles,
2034 represent primary invasive breast cancers with no exposure to
neoadjuvant therapy prior to array analysis. Of these, 1954 cases are
annotated with DMFS time and event. Of note, other clinical
annotation such as treatment type, estrogen receptor status, nodal
status, tumour size, histologic grade and patient age are available for
the majority of cases.
Subtype assignment
Intrinsic subtypes were assigned to samples using the Single Sample
Predictor (SSP) algorithm described by Hu et al (2006) and utilized by
Fan et al (2006). Affymetrix probe sets were matched to the genes
comprising the SSP centroids using UniGene annotation. Prior to batch
correction, the expression data for each gene were mean centered, and
Spearman correlation was used to find the centroid most closely
associated with each tumour sample. In cases where a correlation
greater than 0.1 was not achieved with at least one centroid, a
subtype was not assigned to that sample (n¼92 cases).
Immunohistochemistry and immunofluorescence
TMA blocks containing cores from 98 breast cancer patients were
constructed as described previously (Das et al, 2008; Salto-Tellez et al,
2007) under institutional ethics committee approval for the tissue
array program (NUS-IRB 05-017). Staining was done with anti-
SPINK1 monoclonal antibody (MoBiTec: PSKAN2-0100) at a dilution of
1:1000 for immunohistochemistry and 1:50 for immunofluorescence.
Other antibodies used for immunofluorescence include anti-His (Delta
Biolabs), Alexa 488 goat anti-mouse and Alexa 647 goat anti-rabbitwww.embomolmed.org EMBO Mol Med 3, 451–464(Invitrogen) at a dilution of 1:500. The TMA slides were digitized using
the Ariol SL-50 platform (Applied Imaging Inc., San-Jose, CA). Each slide
was scanned at 20 objective with three filters: red, green and blue
(RGB). The Ariol software then converted these RGB-channel scans into
colour reconstructions for image analysis. For SPINK1 expression, the
Ariol analytical algorithm was trained using the positive controls. The
positivity of the SPINK1 expression was initially confirmed by two
senior pathologists (BP and MST). The training of the Ariol algorithm
was then performed by a pathological assistant (OCW) to ensure that
stromal matrix and adipose cells are excluded from the image analysis.
After the initial program training, the rest of the analysis was
performed without human supervision. Absolute values of expression
were subsequently provided by the software for all the TMA cores.
Previously, we have reported a high level of concordance (k>0.9)
between the Ariol scoring and human observer scoring methods for
immunohistochemistry in a technical journal (Ong et al, 2010). The
positivity of SPINK expression was determined by rank-transforming
all the positive scores of SPINK1 expression into two groups based on
a 50th percentile cutoff. Associations between SPINK1 expression and
clinicopathological features were assessed using the student’s t-test.
All statistical analyses were performed using the SPSS package.
Cell lines, stable overexpression and conditioned media
Human breast cell lines, BT-549, MCF10A, MCF-7 and MDA-MB-231
were obtained from American Type Culture Collection (ATCC) and
maintained at 378C with 5% CO2 with growth medium recommended
by ATCC. Full-length SPINK1 was commercially obtained (Invitrogen:
IOH10627). A 6XHis Tag was added using the primers (-F- 50-
ATGAAGGTAACAGGCATCTTTCTTCTCAGTGCCTT-30) and R2 50-TCAGTGAT-
GATGATGATGGTGGCAAGGCCCAGAT-30). Mutant SPINK1 K18Y was gener-
ated by site-directed mutagenesis kit according to the manufacturer’s
protocol (Calbiochem: QIA58). All clones were confirmed by sequencing
on both strands. PCR products were shuttled into pCR1 2.1-TOPO1
vector (Invitrogen: K4510-20) and further subcloned in mammalian
expression vector pcDNATM3.1(þ) (Invitrogen: V790-20) via restriction
sites NheI and EcoRI. SPINK1 and empty control plasmids were
independently transfected into MCF-7/MDA-MB-231 cells using Lipo-
fectamine 2000. Stable colonies are selected by G418 selection (Sigma).
The clones are referred to MCF-7 SPINK1OE and MB231 SPINK1OE,
respectively, in this study. Insect SF9 cells were obtained from BD
Biosciences and maintained in Grace’s insect media (Invitrogen)
supplemented with fungizone (Invitrogen) and 10% FBS. SPINK1 with
a 30 6XHis tag and K18Ymutant SPINK1 were cloned into pPK30x vector,
and infected into SF9 cells with baculovirus (BD Biosciences) according to
the manufacturer’s protocol (Fig S4 of Supporting information).
Immunoblot analysis
For Western blot analysis, whole cell lysates were prepared using RIPA
buffer. The proteins were separated by SDS–PAGE and transferred to
0.2mm PVDF membrane (Biorad). SPINK1 antibody (MoBiTec: PSKAN2-
0100) was used to probe the membrane at 500 times dilution, and
antibody–protein complex was detected by HRP-conjugated anti-
bodies and ECL (Amersham Biosciences).
siRNA mediated knockdown
RNAi transfection on breast cancer cell lines was carried out using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 2011 EMBO Molecular Medicine 461
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The paper explained
PROBLEM:
In breast cancer treatment, resistance to prevailing drug
treatments prompts a need to find novel molecular targets for
antibody-based or small molecule-based therapeutics. Secretory
factors that drive cancer progression are, therefore, attractive
immunotherapeutic targets. Towards this end, we mined the
expression profiles of 760 primary breast cancers from multiple
patient cohorts to select genes encoding extracellular proteins,
secreted growth factors and cell surface receptors that are
consistently associated with poor patient survival for potential
therapeutic targets. SPINK1 emerged as the most promising
candidate.
RESULTS:
Integrated analysis of microarray profiles of clinically well-
annotated breast tumours identified SPINK1 to be associated
with poor survival in estrogen receptor-positive (ERþ) cases.
Immunohistochemistry showed that SPINK1 was absent in
normal breast, present in early and advanced tumours, and its
expression correlated with poor survival in ERþ tumours. Using
multiple breast cancer cells as model systems, we show that
SPINK1 is essential for cell survival and its forced expression
confers chemoresistance via reduction in pro-apoptotic caspase-
3 protein and induction of the pro-survival gene, BCL2. Intact
protease inhibitor function of SPINK1 is necessary for this
function. Further, SPINK1 increased invasion of breast cancer
cells in vitro and in mouse tail vein assays.
IMPACT:
Our data shows that SPINK1 significantly associates with poor
prognosis in ERþ versus ER patients. Further, high SPINK1
expression in the well-differentiated ERþ lymph node-negative
(LN) group is a highly significant predictor of poor outcome. On
a molecular level, SPINK1 affects multiple aggressive properties
in breast cancer: survival, invasiveness and chemoresistance.
Because SPINK1 effects are abrogated by neutralizing antibodies,
we suggest that SPINK1 is a viable potential therapeutic target in
breast cancer.
462protocol. 3 SPINK1 specific siRNAs were used, C2siRNA (50-CCAA-
GAUAUAUGACCCUGUTT-30) gave the optimal knockdown of SPINK1,
(C1-50-CCAAGGUUUUGAAAUCCCATT-30; and C3-50-GAGGCCAAAU-
GUUACAAUGTT-30). Knockdown efficiency of the siRNAs were checked
using Polymerase Chain Reaction (after reverse transcription) (RT-PCR)
with (SPINK1-F 50-CATCTGCCATATGACCCTTC-30 ; SPINK1-R 50-
GATGCCTGTTACCTTCATGG-3 0; SPINK1-H 5 0-FAM-GACGTGG-
TAAGTGCGGTGCAG-BHQ1-30), GAPDH was internal housekeeping
control. ATG 5 and ATG12 specific siRNAs were purchased from
Applied Biosystems (#s18158-s18160; s17464-s17466).
Cell proliferation and apoptosis assays
Cells were transfected with siRNAs at 100nM for 48 h. Cells were
plated at a density of 5000 cells/well in 96-well plates, and cell
proliferation was measured at various time points in quadruplicate
using WST-1 (Roche: 11644807001) or BrDU (CalBiochem: QIA58)
according to the manufacturer’s protocol. p-Values were obtained by
doing a two-tailed t-test comparing proliferation rates between loss of
gene and scrambled control. For the apoptosis PARP and caspase-3
assay, 5000 cells were plated into each well in a 96-well plate. 5-FU
was then added for a period of 24 h, with eight replicates per
condition. Cells were fixed and blocked with goat serum. Antibodies
anti-cleaved PARP (BD: 552596), anti-active caspase3 (BD:559565),
goat anti-mouse IgG Alexa 488 (Invitrogen: A21121) and goat anti-
rabbit IgG Alexa 647 (Invitrogen: 21244) were used for staining.
Rescue experiments were carried out using SPINK1CM (see below).
Conditioned media
A total of 8–10ml of serum-free DMEM was added to each 15 cm
plate of MCF-7 SPINK1 OE cells (Supporting information Fig 1, 2011 EMBO Molecular Medicineclone 9). Twenty-four hours later, SPINK1CM was collected, centri-
fuged for 5min at 800 rpm at 48C. The CM was warmed to 378C
before use. For SF9 cells, the cells were infected with virus (SPINK1 or
SPINK1-K18Y) at the optimal titer. Three days later, CM was collected
and centrifuged for 3min at 1000 rpm at 48C to remove cells. Vec-CM
was collected in a similar manner from empty vector transfected cells
served as a control. Appropriate volumes of these CM were used in
relevant assays. To neutralize SPINK1, CM was pre-incubated for 2 h at
room temperature with 50 molar excess of the anti-SPINK1
antibody OR IgG. The latter served as another control.
In vitro invasion and migration
Transwell migration and invasion assays were performed using Falcon
FluoroBlok 24-Multiwell inserts (BD Biosciences) with 8mm pores. For
invasion assays, the inserts were coated with 20mg Matrigel (BD
Biosciences) in 80ml serum-free growth medium. For both assays,
30,000 cells in 200ml serum-free growth medium were loaded into
each transwell insert with 750ml complete growth medium or CM or
CM with neutralizing antibody in the lower chamber. After 24 or 48 h,
cells that had migrated or invaded through the pores of the inserts
were fixed with 3.7% formaldehyde, stained with 2.5mg/ml Hoechst
33342 (Invitrogen) for 15min, washed with PBS and counted using
the Target Activation Bioapplication on an ArrayScan VTI (Cellomics).
Field size was 1mm2. For both invasion and migration assays,
experiments were performed with fourfold replication and 10 fields
were scanned per experiment.
Tail vein assay
5105 MB231 SPINK1OE cells or empty vector control cells were
resuspended in 300ml of PBS and injected into the tail vein of Balb/cEMBO Mol Med 3, 451–464 www.embomolmed.org
Research Article
Wendy WeiJia Soon et al.nude mice 12-week-old. Four mice were injected per cell line. Mice
were euthanized 12 weeks later and lung sections were stained with
haematoxylin and eosin. IACUC protocol #070256 was approved by
the Biological Resource Centre, Agency of Science, Technology and
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